The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study

Papers of special note have been highlighted as: • of interest

References

• 1. Chow FC-L, Chok KS-H. Colorectal liver metastases: an update on multidisciplinary approach. World J. Hepatol. 11(2), 150–172 (2019).
  MedlineGoogle Scholar
• 2. Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27(8), 1386–1422 (2016).
  Medline CASGoogle Scholar
• 3. Benson AB, Venook AP, Al-Hawary MM et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 19(3), 329–359 (2021).
  MedlineGoogle Scholar
• 4. Hallet J, Sa Cunha A, Adam R et al. Factors influencing recurrence following initial hepatectomy for colorectal liver metastases. Br. J. Surg. 103(10), 1366–1376 (2016).
  Medline CASGoogle Scholar
• 5. Imai K, Allard M-A, Benitez CC et al. Early recurrence after hepatectomy for colorectal liver metastases: what optimal definition and what predictive factors? Oncologist 21(7), 887–894 (2016).
  MedlineGoogle Scholar
• 6. Fiz F, Viganò L, Gennaro N et al. Radiomics of liver metastases: a systematic review. Cancers (Basel) 12(10), E2881 (2020).
  Medline CASGoogle Scholar
• 7. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology 278(2), 563–577 (2016).
  MedlineGoogle Scholar
• 8. Scapicchio C, Gabelloni M, Barucci A, Cioni D, Saba L, Neri E. A deep look into radiomics. Radiol. Med. 126(10), 1296–1311 (2021).
  MedlineGoogle Scholar
• 9. Coppola F, Faggioni L, Gabelloni M et al. Human, all too human? An all-around appraisal of the ‘artificial intelligence revolution’ in medical imaging. Front. Psychol. 12, 710982 (2021).
  MedlineGoogle Scholar
• 10. Coppola F, Giannini V, Gabelloni M et al. Radiomics and magnetic resonance imaging of rectal cancer: from engineering to clinical practice. Diagnostics (Basel) 11(5), 756 (2021).
  MedlineGoogle Scholar
• 11. Granata V, Fusco R, Barretta ML et al. Radiomics in hepatic metastasis by colorectal cancer. Infect. Agent. Cancer 16(1), 39 (2021).
  MedlineGoogle Scholar
• 12. Cremolini C, Antoniotti C, Rossini D et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 21(4), 497–507 (2020).
  Medline CASGoogle Scholar
• 13. Bettinelli A, Marturano F, Avanzo M et al. A novel benchmarking approach to assess the agreement among radiomic tools. Radiology 303(3), 533–541 (2022).
  MedlineGoogle Scholar
• 14. Zwanenburg A, Vallières M, Abdalah MA et al. The Image Biomarker Standardization Initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 295(2), 328–338 (2020).
  MedlineGoogle Scholar
• 15. Chavent M, Kuentz V, Liquet B, Saracco L. ClustOfVar: An R package for the clustering of variables. https://doi.org/10.48550/arXiv.1112.0295 (2011).
  Google Scholar
• 16. Shah AD, Bartlett JW, Carpenter J, Nicholas O, Hemingway H. Comparison of Random Forest and Parametric Imputation Models for Imputing Missing Data Using MICE: A CALIBER Study. Am J Epidemiol 179(6), 764–774 (2014).
  MedlineGoogle Scholar
• 17. Osterlund P, Salminen T, Soveri L-M et al. Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): a nationwide prospective intervention study. Lancet Reg. Health Eur. 3, 100049 (2021).
  MedlineGoogle Scholar
• 18. Dohan A, Gallix B, Guiu B et al. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. Gut 69(3), 531–539 (2020). • This evaluated the predictive role of radiomic signatures in liver-limited metastatic colorectal cancer (LL-mCRC) patients treated with CT/bev. Of note as one of the first research efforts in the LL-mCRC setting.
  Medline CASGoogle Scholar
• 19. Lubner MG, Stabo N, Lubner SJ et al. CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes. Abdom. Imaging 40(7), 2331–2337 (2015). • It evaluated the prognostic impact of baseline tumour heterogeneity in LL-mCRC patients. Importance attributable to the fundamental analyses conducted on the radiomic features' potential to describe microscopic tumour features.
  MedlineGoogle Scholar
• 20. Ravanelli M, Agazzi GM, Tononcelli E et al. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy. Radiol. Med. 124(9), 877–886 (2019). • LL-mCRC patients treated with CT/bevacizumab analyzed for radiological response in accordance with radiomic features. Importance lies in its pioneering role in the field of radiomics this time investigating response.
  MedlineGoogle Scholar
• 21. Beckers RCJ, Trebeschi S, Maas M et al. CT texture analysis in colorectal liver metastases and the surrounding liver parenchyma and its potential as an imaging biomarker of disease aggressiveness, response and survival. Eur. J. Radiol. 102, 15–21 (2018). • It assessed the prognostic/predictive value of radiomic textures in LL-mCRC patients not only regarding liver metastases but also on tissue microarchitecture.
  Medline CASGoogle Scholar
• 22. Wesdorp NJ, van Goor VJ, Kemna R et al. Advanced image analytics predicting clinical outcomes in patients with colorectal liver metastases: a systematic review of the literature. Surg. Oncol. 38, 101578 (2021).
  Medline CASGoogle Scholar
• 23. Nakanishi R, Oki E, Hasuda H et al. Radiomics texture analysis for the identification of colorectal liver metastases sensitive to first-line oxaliplatin-based chemotherapy. Ann. Surg. Oncol. 28(6), 2975–2985 (2021). • It displayed of radiomic features in LL-mCRC treated with oxaliplatin-based I line.
  MedlineGoogle Scholar
• 24. Ahn SJ, Kim JH, Park SJ, Han JK. Prediction of the therapeutic response after FOLFOX and FOLFIRI treatment for patients with liver metastasis from colorectal cancer using computerized CT texture analysis. Eur. J. Radiol. 85(10), 1867–1874 (2016).
  MedlineGoogle Scholar
• 25. Carles M, Popp I, Starke MM et al. FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation? Radiat. Oncol. 16(1), 46 (2021).
  MedlineGoogle Scholar
• 26. Wang X, Gao W, Li F, Shi W, Li H, Zeng Q. Diffusion kurtosis imaging as an imaging biomarker for predicting prognosis of the patients with high-grade gliomas. Magn. Reson. Imaging 63, 131–136 (2019).
  Medline CASGoogle Scholar
• 27. Rao S-X, Lambregts DM, Schnerr RS et al. CT texture analysis in colorectal liver metastases: a better way than size and volume measurements to assess response to chemotherapy? United European Gastroenterol. J. 4(2), 257–263 (2016).
  Medline CASGoogle Scholar
• 28. Beckers RCJ, Lambregts DMJ, Schnerr RS et al. Whole liver CT texture analysis to predict the development of colorectal liver metastases– a multicentre study. Eur. J. Radiol. 92, 64–71 (2017).
  MedlineGoogle Scholar